GlassScriptPhysician profile
Todd A Staub
NPI 1144505975
$7,387.31
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,647 · 2022: $1,946 · 2023: $2,565 · 2024: $1,230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,742 · Education: $52.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,742.46 |
| Education | $52.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,751.26 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $603.94 | 2021-2024 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $575.02 | 2021-2024 | |
| Janssen Biotech, INC. | $572.60 | 2021-2023 | Tremfya, Stelara, Simponi |
| E.R. Squibb & Sons, L.L.C. | $502.00 | 2022-2024 | Sotyktu |
| Genzyme Corporation | $464.90 | 2021-2024 | |
| Ucb, INC. | $447.32 | 2021-2024 | Cimzia, Bimzelx |
| Leo Pharma INC. | $420.33 | 2021-2024 | Adbry |
| Pfizer INC. | $255.40 | 2021-2024 | |
| Amgen INC. | $250.74 | 2022-2024 | Otezla |
| Lilly USA, LLC | $249.19 | 2021-2024 | Taltz, Olumiant, Zepbound |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $201.49 | 2021-2024 | Arazlo, Cabtreo |
| Sun Pharmaceutical Industries INC. | $190.09 | 2021-2023 | Ilumya, Winlevi |
| Incyte Corporation | $167.72 | 2021-2024 | Opzelura |
| Galderma Laboratories, L.P. | $136.92 | 2021-2024 | Aklief, Oracea |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi US Services INC. | $92.07 | 2023 | |
| Epi Health, LLC | $81.07 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $79.99 | 2021 | |
| Journey Medical Corporation | $53.32 | 2022-2023 | |
| Almirall LLC | $47.72 | 2021-2022 | |
| Genentech USA, INC. | $42.27 | 2021-2022 | |
| Mission Pharmacal Company | $31.80 | 2021-2022 | |
| Dermavant Sciences, INC. | $26.67 | 2024 | Vtama |
| Helsinn Therapeutics (U.S.), INC. | $24.89 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.88 | 2024 | Cyltezo |
| Organogenesis INC. | $21.80 | 2024 | |
| Verrica Pharmaceuticals INC. | $16.14 | 2023 | Ycanth |
| Genentech, INC. | $15.70 | 2023 | Erivedge |
| Merck Sharp & Dohme LLC | $15.45 | 2023 | Keytruda |
| Arcutis Biotherapeutics, INC. | $14.51 | 2023 | |
| Biofrontera INC. | $13.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Staub listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.